

Resource Summary Report

Generated by [dkNET](#) on Aug 20, 2026

Ras antibody [EP1125Y]

RRID:AB_2121042

Type: Antibody

Proper Citation

Abcam Cat# ab52939, RRID:AB_2121042

Antibody Information

URL: http://antibodyregistry.org/AB_2121042

Proper Citation: Abcam Cat# ab52939, RRID:AB_2121042

Target Antigen: HRAS

Host Organism: rabbit

Clonality: monoclonal

Comments: validation status unknown, seller recommendations provided in 2012:western blot, immunoprecipitation, flow cytometry

Antibody Name: Ras antibody [EP1125Y]

Description: This monoclonal targets HRAS

Target Organism: mouse, human

Clone ID: EP1125Y

Antibody ID: AB_2121042

Vendor: Abcam

Catalog Number: ab52939

Record Creation Time: 20250820T010639+0000

Record Last Update: 20250820T100354+0000

Ratings and Alerts

No rating or validation information has been found for Ras antibody [EP1125Y].

No alerts have been found for Ras antibody [EP1125Y].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Juric D, et al. (2026) PI3K γ Inhibitor and Degradar Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(1), 56.

Guo J, et al. (2026) VSIG4 Restricts Hepatocellular Carcinoma Control by Suppressing Tumor-Specific CD8 $^{+}$ T-cell Immunity in the Tumor Microenvironment. *Cancer immunology research*, 14(5), 718.

Zhang J, et al. (2026) Zhigancao decoction alleviates Parkinson's disease via inhibiting TNF/NF- κ B and Ras/ERK-mediated neuroinflammation and apoptosis. *iScience*, 29(1), 114489.

Kochen Rossi J, et al. (2025) The differential interactomes of the KRAS splice variants identify BIRC6 as a ubiquitin ligase for KRAS4A. *Cell reports*, 44(1), 115087.

Fu GQ, et al. (2024) Exosomes derived from vMIP-II-Lamp2b gene-modified M2 cells provide neuroprotection by targeting the injured spinal cord, inhibiting chemokine signals and modulating microglia/macrophage polarization in mice. *Experimental neurology*, 377, 114784.

Chang Y, et al. (2024) The UBE2F-CRL5ASB11-DIRAS2 axis is an oncogene and tumor suppressor cascade in pancreatic cancer cells. *Developmental cell*, 59(10), 1317.

Chiang CY, et al. (2023) Methylation of KRAS by SETD7 promotes KRAS degradation in non-small cell lung cancer. *Cell reports*, 42(9), 113003.

Adams LM, et al. (2023) Mapping the KRAS proteoform landscape in colorectal cancer identifies truncated KRAS4B that decreases MAPK signaling. *The Journal of biological chemistry*, 299(1), 102768.

Venkatanarayan A, et al. (2022) CRAF dimerization with ARAF regulates KRAS-driven tumor growth. *Cell reports*, 38(6), 110351.

Xu Y, et al. (2022) The KRAS-G12D mutation induces metabolic vulnerability in B-cell acute lymphoblastic leukemia. *iScience*, 25(3), 103881.

Schiapparelli LM, et al. (2019) The Retinal Ganglion Cell Transportome Identifies Proteins Transported to Axons and Presynaptic Compartments in the Visual System In Vivo. *Cell*

reports, 28(7), 1935.

Yen I, et al. (2018) Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant Tumors. *Cancer cell*, 34(4), 611.

Kirouac L, et al. (2017) Activation of Ras-ERK Signaling and GSK-3 by Amyloid Precursor Protein and Amyloid Beta Facilitates Neurodegeneration in Alzheimer's Disease. *eNeuro*, 4(2).